Skip to main content

Table 2 Therapeutic peptides and their uses

From: Evaluation of the use of therapeutic peptides for cancer treatment

Peptide name Validation Cell lines examineda Ref.
Antimicrobial peptides
 Magainin II in vitro Bladder cancer cells: RT4 pathologic grade 1, 647 V grade 2, and 486P grade 4 [32]
 NRC-3 and NRC-7 In vitro & in vivo Breast cancer: MDA-MB-231, MDA-MB-468, SKBR3, MCF-7 and paclitaxel resistant MCF-7 (MCF-7-TX400) and murine mammary 4 T1 carcinoma cells [34]
 Buforin IIb In vitro & in vivo Cervical carcinoma (HeLa), leukaemia (Jurkat cells) and lung cancer (NCI-H460) cells [37]
 BR2 in vitro Cervical carcinoma (HeLa), colon cancer (HCT116) and murine melanoma (B16-F10) cells [52]
Cell penetrating peptides
 Dox-TAT in vitro Breast cancer (MCF-7 and MCF-7/ADR) and rat prostate carcinoma (AT3B1) cells [53]
Tumour targeting peptides
 RGD-SSL-Dox In vitro & in vivo Melanoma (A375) and murine (B16-F10) melanoma cells [61]
 LPD-PEG-NGR In vitro & in vivo Fibrosarcoma (HT-1080) cells [66]
Therapeutic peptides target transduction pathway
 PNC-2 and PNC-7 in vitro Pancreatic cancer (MIA-PaCa) cells [109]
 Cardiac natriuretic peptides In vitro & in vivo Pancreatic cancer (HPAC), renal carcinoma (SW156), breast adenocarcinoma (HCCI428), ovarian adenocarcinoma (NIHOVCAR-3), modularly thyroid carcinoma (TT), glioblastoma (LNZTA3WT4) and lung carcinoma (NCI-H1963) cells [111118]
 RGD-PEG-Suc-PD0325901 In vitro & in vivo Glioblastoma (U87MG) cells [126]
 VWCS In vitro Head and neck squamous cell carcinoma (HNSCC) and oral epidermoid carcinoma (KB) cells [140]
 FWCS In vitro Head and neck squamous cell carcinoma (HNSCC) and oral epidermoid carcinoma (KB) cells [141]
Therapeutic peptides target cell cycle
 p16 In vitro Pancreatic cancer (AsPC-1 and BxPC-3) cells [166]
 Bac-7-ELP-p21 In vitro Ovarian carcinoma (SKOV-3) cells [75]
 Pen-ELP-p21 In vitro Cervical carcinoma (HeLa) and ovarian carcinoma (SKOV-3) cells  
Therapeutic peptides induce cell death
 TAT-Bim In vitro & in vivo Murine T-cell lymphoma (EL4), pancreatic cancer (Panc-02) and melanoma (B16-F10) cells [193]
 Poropeptide-Bax In vitro Melanoma (SK-MEL-28) cells [194]
 R8-Bax In vitro & in vivo Cervical carcinoma (HeLa) and murine mammary carcinoma (TS/A) cells [194]
 CT20p-NP In vitro & in vivo Breast cancer (MCF-7 or MDA-MB-231) and colon cancer (HCT-116) cells [195]
 RRM-MV In vitro Squamous cell carcinoma (COLO16) and malignant melanoma (MM96L), and murine melanoma (B16-F10) cells [197, 199]
 RRM-IL12 In vitro Mouse melanoma (B16-F10) cells [197]
Therapeutic peptides target tumour suppressor protein
 PNC-27 In vitro Cervical carcinoma (HeLa), colon cancer (SW1417 and H11299), breast cancer (MDA-MB-453 and MCF-7), osteosarcoma (SAOS2), leukaemia (K562), pancreatic cancer (MIA-PaCa-2) and melanoma (A-2058) cells. Rat k-ras-transformed pancreatic cancer (TUC-3) and transformed endothelial (E49) cells [214, 216, 217]
 PNC-21 In vitro Cervical carcinoma (HeLa), colon cancer (SW1417 and H1299), breast cancer (MDA-MB-453), and osteosarcoma (SAOS2) cells. Rat k-ras-transformed pancreatic cancer (TUC-3) and transformed endothelial (E49) cells [214]
 PNC-28 In vitro & in vivo Breast cancer (MDA-MB-453), colon cancer (H1299 and SW1417), osteosarcoma (SAOS2), cervical carcinoma (HeLa) and pancreatic cancer (MiaPaCa-2) cells. Rat k-ras-transformed pancreatic cancer (TUC-3) and transformed endothelial (E49) cells [214, 219, 232]
 Tat-αHDM2 In vitro & In vivo Melanoma (MM-23, MM-24 and MM-26), retinoblastoma (Y79 and WERI), osteosarcoma (U2OS), and cervical carcinoma (C33A) cells [220]
Therapeutic peptides target transcription factors
 Int-H1-S6A, F8A In vitro Breast cancer (MCF-7) cells [230]
 Pen-ELP-H1 In vitro Breast cancer (MCF-7) cells [76]
 BACl-ELP-H1 In vivo Glioma (U-87 MG and D54) and murine glioma (C6) cells [231]
  1. aUnless specified otherwise, all cell lines are human in origin